These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37881953)

  • 1. Aficamten-A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy.
    Patel J; Wang A; Naidu SS; Frishman WH; Aronow WS
    Cardiol Rev; 2023 Oct; ():. PubMed ID: 37881953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy and the impact of mavacamten.
    Mathai S; Williams L
    Ther Adv Chronic Dis; 2022; 13():20406223221136074. PubMed ID: 36407022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Sebastian SA; Padda I; Lehr EJ; Johal G
    Am J Cardiovasc Drugs; 2023 Sep; 23(5):519-532. PubMed ID: 37526885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management.
    Sykuta A; Yoon CH; Baldwin S; Rine NI; Young M; Smith A
    Ann Pharmacother; 2024 Mar; 58(3):273-285. PubMed ID: 37329113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
    Woodland M; Al-Horani RA
    Cardiovasc Hematol Agents Med Chem; 2023; 21(2):78-83. PubMed ID: 36278454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy.
    Maron MS; Masri A; Choudhury L; Olivotto I; Saberi S; Wang A; Garcia-Pavia P; Lakdawala NK; Nagueh SF; Rader F; Tower-Rader A; Turer AT; Coats C; Fifer MA; Owens A; Solomon SD; Watkins H; Barriales-Villa R; Kramer CM; Wong TC; Paige SL; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Abraham T;
    J Am Coll Cardiol; 2023 Jan; 81(1):34-45. PubMed ID: 36599608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.
    Reyes KRL; Bilgili G; Rader F
    Heart Int; 2022; 16(2):91-98. PubMed ID: 36741099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.
    Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I
    Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
    Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
    Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
    Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
    Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
    Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy.
    Chatur S; Hegde SM
    Curr Opin Cardiol; 2023 Sep; 38(5):424-432. PubMed ID: 37382090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of a single dose of Aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model.
    Sharpe AN; Oldach MS; Kaplan JL; Rivas V; Kovacs SL; Hwee DT; Morgan BP; Malik FI; Harris SP; Stern JA
    J Vet Pharmacol Ther; 2023 Jan; 46(1):52-61. PubMed ID: 36382714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Spertus JA; Fine JT; Elliott P; Ho CY; Olivotto I; Saberi S; Li W; Dolan C; Reaney M; Sehnert AJ; Jacoby D
    Lancet; 2021 Jun; 397(10293):2467-2475. PubMed ID: 34004177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revisiting Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Current Practice and Novel Perspectives.
    Ottaviani A; Mansour D; Molinari LV; Galanti K; Mantini C; Khanji MY; Chahal AA; Zimarino M; Renda G; Sciarra L; Pelliccia F; Gallina S; Ricci F
    J Clin Med; 2023 Sep; 12(17):. PubMed ID: 37685777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.
    Braunwald E; Saberi S; Abraham TP; Elliott PM; Olivotto I
    Eur Heart J; 2023 Nov; 44(44):4622-4633. PubMed ID: 37804245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy of Cardiac Myosin Inhibitors Versus Placebo in Patients With Symptomatic Hypertrophic Cardiomyopathy: A Meta-Analysis and Systematic Review.
    Yassen M; Changal K; Busken J; Royfman R; Schodowski E; Venkataramany B; Khouri SJ; Moukarbel GV
    Am J Cardiol; 2024 Jan; 210():219-224. PubMed ID: 37884110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mavacamten: First Approval.
    Keam SJ
    Drugs; 2022 Jul; 82(10):1127-1135. PubMed ID: 35802255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions.
    Dong T; Alencherry B; Ospina S; Desai MY
    Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy.
    Tian Z; Wang F; Jin W; Zhang Q; Zhou J; Yang P; Wang G; Hsu P; Sun J; Zhang S; Han Y
    BMJ Open; 2023 Jun; 13(6):e071473. PubMed ID: 37336533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.